Physician profile
Ben Odell
NPI 1770677734
$1,900.60
in general payments reported to CMS, 2019-2025
25 companies · $49.50 in 2025
The $49.50 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $439 · 2021: $657 · 2022: $175 · 2023: $125 · 2024: $98.87 · 2025: $49.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $425.62 | 2019-2022 | |
| Abbvie INC. | $319.45 | 2019-2023 | |
| Lilly USA, LLC | $168.53 | 2019-2024 | Zepbound, Mounjaro |
| Pfizer INC. | $141.61 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.89 | 2020-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $114.86 | 2021-2023 | |
| Novo Nordisk INC | $80.23 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $65.42 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $54.85 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $47.92 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $43.74 | 2019-2020 | |
| Eisai INC. | $43.18 | 2020-2022 | |
| Exact Sciences Corporation | $34.16 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $33.10 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $31.62 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.20 | 2019-2023 | Eliquis |
| Paratek Pharmaceuticals, INC. | $18.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.18 | 2022 | |
| Almatica Pharma LLC | $15.34 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.02 | 2022 | |
| Glaxosmithkline, LLC. | $13.93 | 2019 | |
| Merck Sharp & Dohme LLC | $13.33 | 2019 | |
| Dexcom, INC. | $13.00 | 2021 | |
| Shire North American Group INC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Odell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.